Advertisement

Supportive Care in Cancer

, Volume 24, Issue 8, pp 3517–3524 | Cite as

Medical marijuana use in head and neck squamous cell carcinoma patients treated with radiotherapy

  • David A. Elliott
  • Nima Nabavizadeh
  • Jeanna L. Romer
  • Yiyi Chen
  • John M. Holland
Original Article

Abstract

Purpose

The purpose of the study was to better understand why patients with history of head and neck cancer (HNC) treated with radiotherapy are using medical marijuana (MM).

Methods

Established HNC quality of life questionnaires and our own MM quality of life questionnaire were sent to 15 HNC patients treated at our institution who reported using MM. Patients are clinically disease free and currently using MM to manage long-term side effects after curative HNC treatment.

Results

There was a 100 % response rate. Median time from treatment was 45 months (21–136 months). Most patients smoked marijuana (12 patients), while others reported ingestion (4 patients), vaporizing (3 patients), and use of homemade concentrated oil (1 patient). Six patients reported prior recreational marijuana use before diagnosis. MM provided benefit in altered sense, weight maintenance, depression, pain, appetite, dysphagia, xerostomia, muscle spasm, and sticky saliva.

Conclusions

HNC patients report MM use to help with long-term side effects of radiotherapy.

Keywords

Radiotherapy and chemoradiotherapy Quality of life Head and neck squamous cell carcinoma Medical cannabis and medical marijuana Questionnaire 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest. The authors have control of the primary data and agree to a review, if necessary.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29CrossRefPubMedGoogle Scholar
  2. 2.
    Hammerlid E, Bjordal K, Ahlner-Elmqvist M, Jannert M, Kaasa S, Sullivan M, Westin T (1997) Prospective, longitudinal quality-of-life study of patients with head and neck cancer: a feasibility study including the EORTC QLQ-C30. Otolaryngol Head Neck Surg 116:666–673CrossRefPubMedGoogle Scholar
  3. 3.
    Hammerlid E, Silander E, Hornestam L, Sullivan M (2001) Health-related quality of life three years after diagnosis of head and neck cancer–a longitudinal study. Head Neck 23:113–125CrossRefPubMedGoogle Scholar
  4. 4.
    Nguyen NP, Moltz CC, Frank C, Vos P, Smith HJ, Karlsson U, Dutta S, Midyett FA, Barloon J, Sallah S (2004) Dysphagia following chemoradiation for locally advanced head and neck cancer. Ann Oncol 15:383–388CrossRefPubMedGoogle Scholar
  5. 5.
    Pauli N, Johnson J, Finizia C, Andrell P (2013) The incidence of trismus and long-term impact on health-related quality of life in patients with head and neck cancer. Acta Oncol 52:1137–1145CrossRefPubMedGoogle Scholar
  6. 6.
    Hall W, Christie M, Currow D (2005) Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol 6:35–42CrossRefPubMedGoogle Scholar
  7. 7.
    Hashibe M, Morgenstern H, Cui Y, Tashkin DP, Zhang ZF, Cozen W, Mack TM, Greenland S (2006) Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiol Biomark Prev 15:1829–1834CrossRefGoogle Scholar
  8. 8.
    Bostwick JM, Reisfield GM, DuPont RL (2013) Clinical decisions. Medicinal use of marijuana. N Engl J Med 368:866–868CrossRefPubMedGoogle Scholar
  9. 9.
    Engels FK, de Jong FA, Mathijssen RH, Erkens JA, Herings RM, Verweij J (2007) Medicinal cannabis in oncology. Eur J Cancer 43:2638–2644CrossRefPubMedGoogle Scholar
  10. 10.
    Bjordal K, Hammerlid E, Ahlner-Elmqvist M, de Graeff A, Boysen M, Evensen JF, Biorklund A, de Leeuw JR, Fayers PM, Jannert M, Westin T, Kaasa S (1999) Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol 17:1008–1019PubMedGoogle Scholar
  11. 11.
    Janda M, Johnson D, Woelfl H, Trimmel M, Bressmann T, Schrockmayr H, Widder J, Trotti A (2002) Measurement of quality of life in head and neck cancer patients utilizing the quality of life radiation therapy questionnaire. Strahlenther Onkol 178:153–158CrossRefPubMedGoogle Scholar
  12. 12.
    Karasawa K, Sasaki T, Okawa T, Takahashi T, Hayakawa K, Ohizumi Y, Tamaki Y, Makino M, Kobyashi M, Shibayama C, Saitou T, Johnson DJ (2003) Clinical investigation: reliability and validity of the Japanese version of quality of life radiation therapy instrument (QOL-RTI) for Japanese patients with head and neck malignancies. J Oncol Manag 12:18–24PubMedGoogle Scholar
  13. 13.
    Singer S, Arraras JI, Chie WC, Fisher SE, Galalae R, Hammerlid E, Nicolatou-Galitis O, Schmalz C, Verdonck-de Leeuw I, Gamper E, Keszte J, Hofmeister D (2013) Performance of the EORTC questionnaire for the assessment of quality of life in head and neck cancer patients EORTC QLQ-H&N35: a methodological review. Qual Life Res 22:1927–1941CrossRefPubMedGoogle Scholar
  14. 14.
    Trotti A, Johnson DJ, Gwede C, Casey L, Sauder B, Cantor A, Pearlman J (1998) Development of a head and neck companion module for the quality of life-radiation therapy instrument (QOL-RTI). Int J Radiat Oncol Biol Phys 42:257–261CrossRefPubMedGoogle Scholar
  15. 15.
    Bjordal K, de Graeff A, Fayers PM, Hammerlid E, van Pottelsberghe C, Curran D, Ahlner-Elmqvist M, Maher EJ, Meyza JW, Bredart A, Soderholm AL, Arraras JJ, Feine JS, Abendstein H, Morton RP, Pignon T, Huguenin P, Bottomly A, Kaasa S (2000) A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer 36:1796–1807CrossRefPubMedGoogle Scholar
  16. 16.
    Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376CrossRefPubMedGoogle Scholar
  17. 17.
    Fayers PM AN BK, Groenvold M, Curran D, Bottomley A. (2001) The EORTC QLQ-C30 Scoring Manual (3rd Edition). In: Editor (ed)^(eds) Book The EORTC QLQ-C30 Scoring Manual (3rd Edition), City.Google Scholar
  18. 18.
    Payakachat N, Ounpraseuth S, Suen JY (2013) Late complications and long-term quality of life for survivors (>5 years) with history of head and neck cancer. Head Neck 35:819–825CrossRefPubMedGoogle Scholar
  19. 19.
    Schauer GL, Berg CJ, Kegler MC, Donovan DM, Windle M (2015) Assessing the overlap between tobacco and marijuana: trends in patterns of co-use of tobacco and marijuana in adults from 2003-2012. Addict Behav 49:26–32CrossRefPubMedGoogle Scholar
  20. 20.
    Van Dam NT, Earleywine M (2010) Pulmonary function in cannabis users: support for a clinical trial of the vaporizer. Int J Drug Policy 21:511–513CrossRefPubMedGoogle Scholar
  21. 21.
    Bachhuber MA, Saloner B, Cunningham CO, Barry CL (2014) Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern Med 174:1668–1673CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Cobaugh DJ, Gainor C, Gaston CL, Kwong TC, Magnani B, McPherson ML, Painter JT, Krenzelok EP (2014) The opioid abuse and misuse epidemic: implications for pharmacists in hospitals and health systems. Am J Health Syst Pharm 71:1539–1554CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • David A. Elliott
    • 1
  • Nima Nabavizadeh
    • 1
  • Jeanna L. Romer
    • 1
  • Yiyi Chen
    • 2
  • John M. Holland
    • 1
  1. 1.Department of Radiation Medicine, Knight Cancer InstituteOregon Health & Science UniversityPortlandUSA
  2. 2.Department of Public Health & Preventive MedicineOregon Health & Science UniversityPortlandUSA

Personalised recommendations